Correlation between the presence of circulating tumor cells and the pathologic type and staging of non-small cell lung cancer during the early postoperative period

Xie, Zhanqiang; Gao, Xiaotian; Cheng, Kun; Yu, Lishuang

doi:10.3892/ol.2017.6910

Cited by 13 publications

(15 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CTC clusters were found in 9/21 patients (Range 1–6 CTC clusters/mL; 1/4 Stage I, 2/4 Stage II, 2/8 Stage III, 4/5 Stage IV) (Figure 3A) where the size of CTC clusters ranged from 80.26 µm–353.10 µm (Figure 3B). Notably, single CTCs and CTC clusters (Figure 4A) were present at all stages of disease and the presence of CTC clusters increased with an advancement in staging, indicative of a higher burden of disease [32].…”

Section: Resultsmentioning

confidence: 99%

Capture of Circulating Tumour Cell Clusters Using Straight Microfluidic Chips

Kulasinghe

Zhou

Kenny

et al. 2019

Cancers

View full text Add to dashboard Cite

Circulating tumour cells (CTCs) are the metastatic precursors to distant disease in head and neck cancers (HNCs). Whilst the prognostic and predictive value of single CTCs have been well documented, the role of CTC clusters, which potentially have a higher metastatic capacity are limited. In this study, the authors used a novel straight microfluidic chip to focus and capture CTCs. The chip offers high cell recoveries with clinically relevant numbers (10–500 cells/mL) without the need for further purification. Single CTCs were identified in 10/21 patient samples (range 2–24 CTCs/mL), CTC clusters in 9/21 patient samples (range 1–6 CTC clusters/mL) and circulating tumour microemboli (CTM) in 2/21 samples. This study demonstrated that CTC clusters contain EGFR amplified single CTCs within the cluster volume. This novel microfluidic chip demonstrates the efficient sorting and preservation of single CTCs, CTC clusters and CTMs. The authors intend to expand this study to a larger cohort to determine the clinical implication of the CTC subsets in HNC.

show abstract

Section: Resultsmentioning

confidence: 99%

Capture of Circulating Tumour Cell Clusters Using Straight Microfluidic Chips

Kulasinghe

Zhou

Kenny

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…Meanwhile, a study conducted by Xie et al have also indicated that the early diagnosis of metastasis and recurrence of lung cancer can be monitored via the changes of CTC before and after surgery or chemotherapy, which is helpful to improve the follow-up treatment regimen and thus enhance the survival rate. 27 Molecularly characterization of CTC is important to correlate gene mutation with tumor progression and to identify therapeutic targets for personalized therapies. A new research that assessed the degree of genomic similarity between pulmonary venous CTC (PV-CTC) in surgical resection, primary tumor and metastatic tumor has reported that CTC as a micrometastase is associated with tumor recurrence.…”

Section: Biofunction Of Gene Mutations In the Ctc Genomementioning

confidence: 99%

<p>Circulating Tumor Cells as a Biomarker to Assist Molecular Diagnosis for Early Stage Non-Small Cell Lung Cancer</p>

He¹,

Shi²,

Schmidt³

et al. 2020

CMAR

View full text Add to dashboard Cite

Background and Objective: Compared with tissue biopsy, liquid biopsy is the most preferable non-invasive promising method in personalized medicine, although it has many limitations in isolating circulating tumor cells (CTC). Lung cancer associated mortality is drastically increased due to a shortfall of early-stage detection, which remains a challenge. Herein, we aimed to detect lung cancer at an early-stage using CellCollector device. Methods: 39,627 volunteers underwent low-dose computed tomography; 2508 cases with pulmonary nodules and 7080 with no pulmonary nodules were chosen. After follow-up, 24 patients were diagnosed with early-stage non-small cell lung cancer (NSCLC), and subjected to CTC detection using CellCollector, along with 72 healthy volunteers. Immunofluorescence staining for EpCAM/CKs and CD45 were performed for CTC validation. Results: Fifteen out of twenty-four (stage I, n = 18; stage II, n = 6) early-stage lung cancer patients were found to be CTC-positive, whereas no CTC was found in the control group. Genetic mutation of TP53, ERBB2, PDGFRA, CFS1R and FGFR1 in the CTC revealed 71.6% of the mutation sites similar to the tumor tissues of 13 patients. Molecular characterization revealed higher expression of protein PD-LI in CTC (40%) as compared to tumor tissue (26.7%). Moreover, CTC clusters were detected in 40% of patients. Conclusion: CTC detection using the CellCollector in early-stage NSCLC had a relative high capture rate. Moreover, CTC analysis is a prospective setting for molecular diagnostic in cases when tumor tissue biopsy is not desirable.

show abstract

“…LUAD is often metastatic and has a relatively poor prognosis [4]. Chemotherapy, surgery, and radiotherapy are traditional treatments for LUAD [5,6], but the recurrence of early post-operative lung cancer patients are still very high [7]. Meanwhile, chemotherapy and targeted therapies have extensive drug resistance [8,9].…”

Section: Introductionmentioning

confidence: 99%

STEAP1 facilitates metastasis and epithelial–mesenchymal transition of lung adenocarcinoma via the JAK2/STAT3 signaling pathway

Huo

Shang

et al. 2020

Bioscience Reports

View full text Add to dashboard Cite

Six-transmembrane epithelial antigen of prostate-1 (STEAP1) is a relatively newly identified gene target from prostate cancer, breast cancer, and gastric cancer. However, functions of STEAP1 in lung adenocarcinoma (LUAD) are still unknown. In the present study, we explored the molecular and cellular mechanisms of STEAP1 in LUAD. Western blot and Q-PCR were conducted to detect the protein and mRNA expressions respectively. The cell proliferation was tested by CCK8 assay. The effects of STEAP1 on the metastasis and epithelial–mesenchymal transition (EMT) of LUAD were evaluated by EdU assay, wound healing assay, and transwell migratory assay. H1650, H358, HCC827, H1299, H23, A549, H1693 were selected as human LUAD cell lines in the study. Results have shown that STEAP1 expression was up-regulated in LUAD cells compared with normal lung epithelial cells. Knockdowning of STEAP1 suppressed the proliferation, migration, and invasion of LUAD epithelial cells. Importantly, after comparing the proliferation, migration, and invasion of LUAD to the corresponding control groups treated in STAT3 inhibitor ADZ1480, we found that STEAP1 regulates EMT via Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway. In conclusion, STEAP1 can serve as a therapeutic target, and it may have important clinical implications for LUAD treatment.

show abstract

Correlation between the presence of circulating tumor cells and the pathologic type and staging of non-small cell lung cancer during the early postoperative period

Cited by 13 publications

References 29 publications

Capture of Circulating Tumour Cell Clusters Using Straight Microfluidic Chips

Capture of Circulating Tumour Cell Clusters Using Straight Microfluidic Chips

<p>Circulating Tumor Cells as a Biomarker to Assist Molecular Diagnosis for Early Stage Non-Small Cell Lung Cancer</p>

STEAP1 facilitates metastasis and epithelial–mesenchymal transition of lung adenocarcinoma via the JAK2/STAT3 signaling pathway

Contact Info

Product

Resources

About